After announcing a review of “strategic alternatives” for its contract manufacturing division back in March, Madrid-based drugmaker Laboratorios Farmacéuticos Rovi now says it has received buyout offers for the unit. Specifically, Spanish newspaper Expansion reported that five bidders are angling for a potential acquisition of the Rovi contract manufacturing outfit. The report put a potential deal value at 3.5 billion euros ($3.74 billion). According to Expansion, the parties with initial offers in the race are Antin Infrastructure Partners, Cinven, CVC Capital Partners, KKR and Permira, all of which are now in the due diligence stage.
Read the full article: Spain’s Rovi Receives Offers for Potential Sale of €2B-Plus CDMO Group //
Source: https://www.fiercepharma.com/manufacturing/rovis-potential-cdmo-sale-attracts-private-equity-bidders-report